An open label phase 3 study of fortigel [ProStrakan] testosterone gel 2% in hypogonadal males.

Trial Profile

An open label phase 3 study of fortigel [ProStrakan] testosterone gel 2% in hypogonadal males.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Pharmacokinetics; Registrational
  • Acronyms FORTIFY
  • Sponsors ProStrakan
  • Most Recent Events

    • 08 May 2009 Planned number of patients changed from 140 to 149 as reported by ClinicalTrials.gov.
    • 08 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top